Convertibles Calendar: Pacira Pharmaceuticals to price $300 million convertibles

March 7

PACIRA PHARMACEUTICALS INC.:

• $300 million of five-year convertible senior notes

• $45 million greenshoe

• Talked at 2.75%-2.875%, up 27.5%-32.5%

• Rule 144A

• J.P. Morgan Securities LLC, Jefferies & Co. and RBC Capital Markets LLC

• Non-callable for three years, then provisionally callable at 130% price hurdle

• Coupon make-whole provision

• Net-share settlement

• Proceeds for repurchase of existing Pacira 3.25% convertibles due 2019, with remaining proceeds for general corporate purposes, including working capital, and R&D

• Parsippany, N.J.-based specialty pharmaceutical company

• Nasdaq: PCRX

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.